Background: Febrile neutropenia (FN) remains a leading cause of morbidity and mortality in pediatric patients with high-risk hematologic disorders, particularly in low- and middle-

income countries (LMICs), where antimicrobial resistance limits treatment options.

Granulocyte transfusion (GT) is considered adjunctive therapy, but pediatric data from

LMICs are limited.

Methods: This 15-year retrospective cohort study included pediatric patients (<18 years)

with severe neutropenic infections treated at a national tertiary referral center in Thailand

(2009-2023). Patients received GT plus antimicrobial therapy or antimicrobial therapy alone.

The primary outcome was 30-day survival. The analyzes included multivariable logistic

regression, Cox regression, propensity score matching (PSM) and inverse probability of

treatment weighting (IPTW).

Results: Among 54 patients (26 GT, 28 control), GT was associated with an improvement in

30-day survival in the full cohort (OR 0.105, 95% CI: 0.016 0.700; p = 0.020). IPTW

confirmed this association (OR 0.099; p = 0.001), with consistent results in the PM analysis

(OR 0.157; p = 0.028). In the high-risk hematologic subgroup (n = 48), GT was associated

with increased survival (95.2% vs 61.9%; HR 0.105; p = 0.034). GT also accelerated the

resolution of fever (HR 2.24; p = 0.028), febrile neutropenia recovery (HR 2.35; p = 0.017),

and absolute neutrophil count (ANC) recovery (HR 2.10; p = 0.047). No serious transfusion-

related adverse events were observed.

Conclusions: GT was associated with improved survival and faster clinical recovery in

pediatric FN. These real-world LMIC data support GT as a feasible adjunctive therapy and

warrant prospective validation.

Keywords: granulocyte transfusion, febrile neutropenia, pediatric hematology, LMIC,

survival, infection

Key Message

Granulocyte transfusion significantly improved 30-day survival in pediatric febrile neutropenia, with GT recipients achieving 92.3% versus 65.4% survival at 30 days (adjusted OR 0.105; p = 0.020). Secondary outcomes showed a trend toward better 90-day survival (p = 0.071), faster fever resolution (HR 2.24; p = 0.028), accelerated FN recovery (HR 2.35; p = 0.017), and quicker ANC recovery (HR 2.10; p = 0.047), with no serious adverse events observed.

This content is only available as a PDF.
2025
Sign in via your Institution